[ad_1]
The Pfizer Corona vaccine candidate is promoting success with up to 90% efficacy, far superior to the typical efficacy of the seasonal flu vaccine, which was 29% effective in the 2018-2019 flu season, according to the CDC.
Data from the Centers for Disease Control and Prevention (CDC) showed that the flu vaccine was 48% effective in the 2015-2016 season, but this number steadily decreased to 40% in 2016-2017, to 38% in 2017-2018. and 29% in 2018-2019.
Preliminary data for the 2019-2020 flu season showed that the latest vaccine was 39% effective, numbers which mean that only 39% of people who were vaccinated in 2019-2020 did not catch the flu.
According to a report by the American newspaper “NY Post”, with the new coronavirus vaccine “Corona” produced by Pfizer, which has an effective rate of 90%, this means that the vast majority of those who have received the vaccine have placed an end to the development of protective antibodies against them. Within 28 days, this will at least temporarily protect the infection.
A recent study, awaiting peer review, said antibody immunity lasts at least 6 months and scientists are already investigating whether the Corona vaccine should be given every year like the flu vaccine, NBC reported.
Although no vaccine is currently ready on the market for COVID-19, Pfizer expects to have 50 million doses of the BNT162b2 vaccine ready by the end of 2020 and up to 1.3 billion doses available in 2021.
The vaccine efficacy rate has reached 90%, which is much higher than the 50% required for the Corona virus vaccine by the Food and Drug Administration, and is gradually approaching the high levels of immunity provided by the measles and polio vaccine.
The company said Pfizer’s coronavirus vaccine currently requires two booster doses.
.
[ad_2]
Source link
